ClinicalTrials.gg
RecruitingNCT07024927CARUpdated Jun 4, 2026

Complex Arrhythmia Registry

An observational study in Atrial Fibrillation (AF) and Ventricular Tachycardia (VT), sponsored by Beijing Anzhen Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Beijing Anzhen Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
7th of 12
4,000 · median 7,000
Started
2025
with 10 others
Observational
12 of 36
9 open now
Primary completion
2032-06
later than 19 of 25 live
Registered
21st of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 11 that started in 2025, is one of 12 observational ones, reaches primary completion later than 19 of the 25 other live ones, and was the 21st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.

Read the detailed description

With the advancement of cardiac electrophysiology, the latest radiofrequency ablation technologies have played a significant role in the treatment of AF and VT. However, long-term outcome data on the application of these advanced techniques in Chinese patients still remains limited. The prospective, non-randomized, multicenter observational registry study will be divided into two cohorts:

  1. The AF Cohort will focus on evaluating the effectiveness and safety of different ablation workflows. It aims to redefine the relationship between AF recurrence and long-term outcomes using AF burden, thereby further optimizing treatment strategies for AF.
  2. The VT Cohort will primarily assess the application effects of novel technologies in VT treatment.

These data will provide critical reference information for future diagnostic and management strategies for complex arrhythmias.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Ventricular Tachycardia (VT)

Keywords

  • atrial fibrillation
  • ventricular tachycardia
  • ablation
  • registry study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 4,000 patients who first undergo ablation will be included and divided into three cohorts: 1,000 in the PAF cohort, 2,000 in the PeAF cohort, and 1,000 in the organic VT cohort.

Eligibility criteria

  1. Atrial Fibrillation (AF) Cohort:

    • Inclusion Criteria (Patients must meet ALL of the following criteria):

      1. Age ≥ 18 years.
      2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).
      3. Scheduled to undergo first-time catheter ablation for AF.
      4. Procedure to be performed using a 3D mapping system.
      5. Provision of signed written for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
    • Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):

      1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).
      2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).
      3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure.
      4. Severe active infection (e.g., septic shock, sepsis).
      5. to anticoagulation therapy.
      6. Current participation in another interventional clinical trial that may confound the results of this study.
      7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
  2. Ventricular Tachycardia (VT) Cohort

    • Inclusion Criteria (Patients must meet ALL of the following criteria):

      1. Age ≥ 18 years.
      2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:
      3. Ischemic heart disease (e.g., prior MI, coronary artery disease).
      4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).
      5. Scheduled to undergo first-time catheter ablation for VT.
      6. Procedure to be performed using a 3D mapping system.
      7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.
    • Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):

      1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).
      2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).
      3. Cardiac surgery within 60 days prior to the planned ablation procedure.
      4. Severe coagulopathy (e.g., count \< 50 x 10⁹/L, disseminated intravascular coagulation (DIC)).
      5. Severe heart failure with (LVEF) \< 20%.
      6. Severe active infection (e.g., septic shock, sepsis).
      7. Current participation in another interventional clinical trial that may confound the results of this study.
      8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • PAF

    Paroxysmal atrial fibrillation

    Procedure: AF ablation

  • PeAF

    Persistent atrial fibrillation

    Procedure: AF ablation

  • VT

    Ventricular tachycardia

    Procedure: VT ablation

Interventions

  • ProcedureAF ablation

    Catheter ablation will be performed under general anesthesia or local anesthesia. Pulmonary vein isolation (PVI) was performed in all patients. Beyond this mandatory step, the specific ablation strategy/protocol and ablation parameters/settings will be determined at the discretion of the operating physicians at each participating center.

  • ProcedureVT ablation

    For patients with hemodynamically stable VT, comprehensive chamber mapping (including activation mapping, substrate mapping, and entrainment mapping) is recommended. This aims to elucidate the VT activation sequence and identify the critical isthmus. Precise ablation targeting the isthmus should be performed to terminate the VT. For patients with hemodynamically unstable VT, substrate mapping during sinus rhythm can be performed first. This includes identification of low-voltage zones and abnormal electrograms (e.g., late potentials, local abnormal ventricular activities - LAVAs). Targeted substrate modification ablation should then be conducted based on the mapping findings. For all patients, complete substrate mapping is recommended after VT termination.

06

What researchers measure

Primary outcomes

  1. Freedom from any documented atrial arrhythmia in 12 months after the index ablation procedure

    Time frame: From the end of the 3-month blanking period post-ablation to the 12-month follow-up

  2. Composite outcomes of ventricular tachycardia recurrence, cardiovascular hospitalization, or death during the 12-month follow-up

    Recurrent ventricular tachycardia is defined as any appropriate implantable cardiac defibrillation therapy (shock or antitachycardia pacing) or documented sustained monomorphic ventricular tachycardia \>30 seconds. Cardiovascular rehospitalization is defined as a hospital admission after the randomly assigned procedure for heart failure, procedure-associated complications, or arrhythmic causes during the 12-month follow-up.

    Time frame: 12 months

07

Study locations

1 of 2 sites recruiting
  • No. 2 Anzhen Rd, Chaoyang District, 100029
    Beijing, Beijing Municipality 100029, China
    Recruiting
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2032, 80 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 80 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Oct 21, 2025
Primary completionEst.
Jun 2032
CompletionEst.
Jun 2032
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024927
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Oct 21, 2025
Primary completion
Jun 2032 (estimated)
Completion
Jun 2032 (estimated)
Last update
Jun 4, 2026

Study contacts

Deyong Long, MD
Contact
dragon2008@vip.sina.com
+86 (010) 84005361
Deyong Long
Contact
dragon2008@vip.sina.com
+86 (010) 84005361
Deyong Long
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion